$COO

Kurzius Lawrence Erik purchased $539K of COO

Kurzius Lawrence Erik purchased 10,000 shares of COOPER COMPANIES, INC. (COO) at $53.92 ($0.54M total) on 2026-09-14.

Original reporting
SEC EDGAR · Kurzius Lawrence Erik
Published Sep 15, 2026, 8:53 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 15, 2026, 9:03 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$COO
Bullish
medium confidence
Mentioned
$COO
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$COOBullishLow
01

Why it matters

First public disclosure of director's share purchase, modest size.

02

Market read

Small insider purchase, limited immediate market effect.

03

What to watch

No disclosed 10b5-1 plan; could be opportunistic buying.

Relevance 6/10Novelty 5/10Timing: filing date 2026-09-15

Background

SEC Form 4 filing discloses insider transaction for Cooper Companies.

Company-level read

Ticker impact

$COOBullishMedium confidence
Context

Director Kurzius purchased 10,000 shares at $53.915 each, total $539,150.

Expected impact

Potential slight uptick in COO stock.

Evidence & confidence

Purchase size is modest relative to market cap, but director involvement adds weight.

Market effects

Minimal impact on healthcare equipment sector.

U.S. market only.

Low

Counterpoint

Purchase may be routine portfolio rebalancing, not a strong signal.

Key entities

  • Cooper Companies, Inc.

    Healthcare device manufacturer.

  • Kurzius Lawrence Erik

    Director of Cooper Companies.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$COOMedAI 8/10

A Failed Auction and a 15% Drop: Is Cooper Companies (COO) a Value Trap or a Bargain?

Cooper Companies (COO) ended its 9-month effort to sell CooperSurgical after bids undervalued the business, according to management. The stock dropped 15% to a 52-week low near $51 after a Q3 miss and cut outlook. The company's core contact lens business, CooperVision, posted flat organic revenue growth, contributing to the guidance cut. Management authorized a $1B share repurchase program, while Bank of America questioned the valuation. COO reported record Q3 free cash flow of $273M.

$COOMedAI 8/10

The Cooper Companies (COO) Faces Near-Term Pressure from Slowing Contact Lens Demand

The Cooper Companies (COO) lowered its fiscal 2026 profit and revenue forecasts due to weaker-than-expected contact lens demand, with adjusted EPS now expected at $4.51–$4.55 and revenue at $4.23–$4.25 billion. Q3 revenue was $1.07 billion, missing estimates, though adjusted EPS beat at $1.15. The company cited U.S. channel inventory reductions as a key factor and decided to retain CooperSurgical.